Yadav M, Sharma A, Patne K, Tabasum S, Suryavanshi J, Rawat L
Signal Transduct Target Ther. 2025; 10(1):37.
PMID: 39924521
PMC: 11808115.
DOI: 10.1038/s41392-024-02121-7.
Kamara S, Wen H, Guo Y, Liu Y, Liu L, Du W
Cells. 2024; 13(22).
PMID: 39594573
PMC: 11592995.
DOI: 10.3390/cells13221823.
Crossman B, Harmon R, Kostecki K, McDaniel N, Iida M, Corday L
J Clin Med. 2024; 13(20).
PMID: 39457986
PMC: 11508784.
DOI: 10.3390/jcm13206036.
Diawara M, Martin L
Mol Biol Rep. 2024; 51(1):982.
PMID: 39271559
DOI: 10.1007/s11033-024-09934-3.
Yuan K, Wu Q, Yao Y, Shao J, Zhu S, Yang J
Transl Stroke Res. 2024; .
PMID: 39103659
DOI: 10.1007/s12975-024-01282-5.
Curcumin in Cancer and Inflammation: An In-Depth Exploration of Molecular Interactions, Therapeutic Potentials, and the Role in Disease Management.
Moon D
Int J Mol Sci. 2024; 25(5).
PMID: 38474160
PMC: 10932100.
DOI: 10.3390/ijms25052911.
NF-κB: Governing Macrophages in Cancer.
Cornice J, Verzella D, Arboretto P, Vecchiotti D, Capece D, Zazzeroni F
Genes (Basel). 2024; 15(2).
PMID: 38397187
PMC: 10888451.
DOI: 10.3390/genes15020197.
Targeting AXL induces tumor-intrinsic immunogenic response in tyrosine kinase inhibitor-resistant liver cancer.
Xie Y, Wu H, He Y, Liu L, Huang I, Zhou L
Cell Death Dis. 2024; 15(2):110.
PMID: 38310091
PMC: 10838288.
DOI: 10.1038/s41419-024-06493-0.
Repurposing of Zika virus live-attenuated vaccine (ZIKV-LAV) strains as oncolytic viruses targeting human glioblastoma multiforme cells.
Victorio C, Novera W, Ganasarajah A, Ong J, Thomas M, Wu J
J Transl Med. 2024; 22(1):126.
PMID: 38308299
PMC: 10835997.
DOI: 10.1186/s12967-024-04930-4.
Cholinergic signaling via muscarinic M1 receptor confers resistance to docetaxel in prostate cancer.
Wang J, Wei J, Pu T, Zeng A, Karthikeyan V, Bechtold B
Cell Rep Med. 2024; 5(2):101388.
PMID: 38262412
PMC: 10897519.
DOI: 10.1016/j.xcrm.2023.101388.
Receptor tyrosine kinase gene expression profiling of orbital rhabdomyosarcoma unveils MET as a potential biomarker and therapeutic target.
Chauhan S, Sen S, Irshad K, Kashyap S, Pushker N, Meel R
Hum Cell. 2023; 37(1):297-309.
PMID: 37914903
DOI: 10.1007/s13577-023-00993-5.
Primary and acquired resistance to first-line therapy for clear cell renal cell carcinoma.
Astore S, Baciarello G, Cerbone L, Calabro F
Cancer Drug Resist. 2023; 6(3):517-546.
PMID: 37842234
PMC: 10571064.
DOI: 10.20517/cdr.2023.33.
Assessing the epithelial-to-mesenchymal plasticity in a small cell lung carcinoma (SCLC) and lung fibroblasts co-culture model.
Dhungel N, Youngblood R, Chu M, Carroll J, Dragoi A
Front Mol Biosci. 2023; 10:1096326.
PMID: 36936987
PMC: 10022497.
DOI: 10.3389/fmolb.2023.1096326.
AXL Inhibitors: Status of Clinical Development.
Bhalla S, Gerber D
Curr Oncol Rep. 2023; 25(5):521-529.
PMID: 36920638
PMC: 11161200.
DOI: 10.1007/s11912-023-01392-7.
AXL upregulates c‑Myc expression through AKT and ERK signaling pathways in breast cancers.
Sun X, Chen H, You S, Tian Z, Wang Z, Liu F
Mol Clin Oncol. 2023; 18(3):22.
PMID: 36844467
PMC: 9944620.
DOI: 10.3892/mco.2023.2618.
Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancer.
Hu Y, Paris S, Bertolet G, Barsoumian H, He K, Sezen D
J Nanobiotechnology. 2022; 20(1):417.
PMID: 36123677
PMC: 9484155.
DOI: 10.1186/s12951-022-01621-4.
AXL Inhibits Proinflammatory Factors to Relieve Rheumatoid Arthritis Pain by Regulating the TLR4/NF-B Signaling Pathway.
Zhou G, Li H
Evid Based Complement Alternat Med. 2022; 2022:7625739.
PMID: 35983008
PMC: 9381196.
DOI: 10.1155/2022/7625739.
Integrin β3 Promotes Resistance to EGFR-TKI in Non-Small-Cell Lung Cancer by Upregulating AXL through the YAP Pathway.
Sun Q, Lu Z, Zhang Y, Xue D, Xia H, She J
Cells. 2022; 11(13).
PMID: 35805163
PMC: 9265629.
DOI: 10.3390/cells11132078.
Endocytic trafficking of GAS6-AXL complexes is associated with sustained AKT activation.
Poswiata A, Kozik K, Miaczynska M, Zdzalik-Bielecka D
Cell Mol Life Sci. 2022; 79(6):316.
PMID: 35622156
PMC: 9135597.
DOI: 10.1007/s00018-022-04312-3.
GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis.
Bruce S, Cho K, Noia H, Lomonosova E, Stock E, Oplt A
Mol Cancer Ther. 2022; 21(8):1348-1359.
PMID: 35588308
PMC: 9370070.
DOI: 10.1158/1535-7163.MCT-21-0704.